And any time youve experienced a dose-related adverse event, nausea, vomiting, or dizziness, that was more severe than expected
Based on target consumer, GLP-1 Users for Weight Management represent approximately 31.80% share in 2026, driven by the high adoption of GLP-1 agonists specifically for weight loss and the corresponding need for protein, hydration, and micronutrient support
In summary, effective January 1, 2026, CMS will reimburse 547 surgical procedures if performed in an ASC CPL that were previously limited to inpatient or hospital outpatient department (HOPD) settings
To view a copy of this licence, visit About this article Cite this article Wicik, Z., Nowak-Szwed, A., Eyileten, C